Interferons and scleroderma-A new clue to understanding the pathogenesis of scleroderma?

Immunology Letters

Volumn 118, Issue 2, 2008, Pages 110-115

  Coelho, Luiz Felipe Leomil ^a   de Oliveira, Jaquelline Germano ^b   Kroon, Erna Geessien ^b  

^a Centro de Ciências da Saú   (Brazil)

^b Instituto de Ciencias Biologicas   (Brazil)

Author keywords

Dendritic cell; Interferons; Scleroderma

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; GAMMA INTERFERON; INTERFERON; MESSENGER RNA;

ANTIANGIOGENIC ACTIVITY; AUTOIMMUNE DISEASE; CD4+ T LYMPHOCYTE; DENDRITIC CELL; DISEASE COURSE; HEPATITIS C; HUMAN; IMMUNOMODULATION; IMMUNOPATHOGENESIS; IMMUNOREGULATION; INTERFERON PRODUCTION; LYMPHOCYTIC INFILTRATION; MOLECULAR RECOGNITION; MULTIPLE SCLEROSIS; MYELOPROLIFERATIVE DISORDER; NATURAL KILLER T CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SYSTEMIC SCLEROSIS;

AUTOIMMUNE DISEASES; HUMANS; INTERFERONS; SCLERODERMA, SYSTEMIC;

EID: 44649165677     PISSN: 01652478     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.imlet.2008.03.016     Document Type: Review

References (95)

1. Denton C.P., and Black C.M. Scleroderma-clinical and pathological advances. Best Pract Res Clin Rheumatol 18 (2004) 271-290
2. Jimenez S.A., and Derk C.T. Following the molecular pathways toward an understanding of the pathogenesis of systemic sclerosis. Ann Intern Med 140 (2004) 37-50
3. Steen V.D. Systemic sclerosis. Rheum Dis Clin North Am 16 (1990) 641-654
4. Sontheimer R.D. Skin manifestations of systemic autoimmune connective tissue disease: diagnostics and therapeutics. Best Pract Res Clin Rheumatol 18 (2004) 429-462
5. Mayes M.D. Classification and epidemiology of scleroderma. Semin Cutan Med Surg 17 (1998) 22-26
6. Mayes M.D., and Trojanowska M. Genetic factors in systemic sclerosis. Arthritis Res Ther 9 Suppl 2 (2007) S5
7. Varga J., and Abraham D. Systemic sclerosis: a prototypic multisystem fibrotic disorder. J Clin Invest 117 (2007) 557-567
8. Guiducci S., Giacomelli R., and Cerinic M.M. Vascular complications of scleroderma. Autoimmun Rev 6 (2007) 520-523
9. Abraham D., and Distler O. How does endothelial cell injury start? The role of endothelin in systemic sclerosis. Arthritis Res Ther 9 Suppl 2 (2007) S2
10. Gabrielli A., Svegliati S., Moroncini G., and Avvedimento E.V. Pathogenic autoantibodies in systemic sclerosis. Curr Opin Immunol 19 (2007) 640-645
11. Gabrielli A., Svegliati S., Moroncini G., Luchetti M., Tonnini C., and Avvedimento E.V. Stimulatory autoantibodies to the PDGF receptor: a link to fibrosis in scleroderma and a pathway for novel therapeutic targets. Autoimmun Rev 7 (2007) 121-126
12. Baroni S.S., Santillo M., Bevilacqua F., Luchetti M., Spadoni T., Mancini M., et al. Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis. N Engl J Med 354 (2006) 2667-2676
13. Sakkas L.I., and Platsoucas C.D. Is systemic sclerosis an antigen-driven T cell disease? Arthritis Rheum 50 (2004) 1721-1733
14. Krieg T., Abraham D., and Lafyatis R. Fibrosis in connective tissue disease: the role of the myofibroblast and fibroblast-epithelial cell interactions. Arthritis Res Ther 9 Suppl 2 (2007) S4
15. Trojanowska M., and Varga J. Molecular pathways as novel therapeutic targets in systemic sclerosis. Curr Opin Rheumatol 19 (2007) 568-573
16. Ihn H. Autocrine TGF-beta signaling in the pathogenesis of systemic sclerosis. J Dermatol Sci 49 (2008) 103-113
17. Pannu J., Gardner H., Shearstone J.R., Smith E., and Trojanowska M. Increased levels of transforming growth factor beta receptor type I and up-regulation of matrix gene program: a model of scleroderma. Arthritis Rheum 54 (2006) 3011-3021
18. Verrecchia F., Mauviel A., and Farge D. Transforming growth factor-beta signaling through the Smad proteins: role in systemic sclerosis. Autoimmun Rev 5 (2006) 563-569
19. Pannu J., Gore-Hyer E., Yamanaka M., Smith E.A., Rubinchik S., Dong J.Y., et al. An increased transforming growth factor beta receptor type I:type II ratio contributes to elevated collagen protein synthesis that is resistant to inhibition via a kinase-deficient transforming growth factor beta receptor type II in scleroderma. Arthritis Rheum 50 (2004) 1566-1577
20. Dong C., Zhu S., Wang T., Yoon W., Li Z., Alvarez R.J., et al. Deficient Smad7 expression: a putative molecular defect in scleroderma. Proc Natl Acad Sci USA 99 (2002) 3908-3913
21. Leask A., Denton C.P., and Abraham D.J. Insights into the molecular mechanism of chronic fibrosis: the role of connective tissue growth factor in scleroderma. J Invest Dermatol 122 (2004) 1-6
22. Stark G.R., Kerr I.M., Williams B.R., Silverman R.H., and Schreiber R.D. How cells respond to interferons. Annu Rev Biochem 67 (1998) 227-264
23. Kontsek P., Karayianni-Vasconcelos G., and Kontsekova E. The human interferon system: characterization and classification after discovery of novel members. Acta Virol 47 (2003) 201-215
24. Uze G., and Monneron D. IL-28 and IL-29: newcomers to the interferon family. Biochimie 89 (2007) 729-734
25. Borden E.C., Sen G.C., Uze G., Silverman R.H., Ransohoff R.M., Foster G.R., et al. Interferons at age 50: past, current and future impact on biomedicine. Nat Rev Drug Discov 6 (2007) 975-990
26. Uze G., Schreiber G., Piehler J., and Pellegrini S. The receptor of the type I interferon family. Curr Top Microbiol Immunol 316 (2007) 71-95
27. Brierley M.M., and Fish E.N. Review: IFN-alpha/beta receptor interactions to biologic outcomes: understanding the circuitry. J Interferon Cytokine Res 22 (2002) 835-845
28. Chawla-Sarkar M., Lindner D.J., Liu Y.F., Williams B.R., Sen G.C., Silverman R.H., et al. Apoptosis and interferons: role of interferon-stimulated genes as mediators of apoptosis. Apoptosis 8 (2003) 237-249
29. de Veer M.J., Holko M., Frevel M., Walker E., Der S., Paranjape J.M., et al. Functional classification of interferon-stimulated genes identified using microarrays. J Leukoc Biol 69 (2001) 912-920
30. Theofilopoulos A.N., Baccala R., Beutler B., and Kono D.H. Type I interferons (alpha/beta) in immunity and autoimmunity. Annu Rev Immunol 23 (2005) 307-336
31. Baccala R., Kono D.H., and Theofilopoulos A.N. Interferons as pathogenic effectors in autoimmunity. Immunol Rev 204 (2005) 9-26
32. Crow M.K., and Kirou K.A. Interferon-alpha in systemic lupus erythematosus. Curr Opin Rheumatol 16 (2004) 541-547
33. Devendra D., and Eisenbarth G.S. Interferon alpha--a potential link in the pathogenesis of viral-induced type 1 diabetes and autoimmunity. Clin Immunol 111 (2004) 225-233
34. Wu Z., Biro P.A., Mirakian R., Hammond L., Curcio F., Ambesi-Impiombato F.S., et al. HLA-DMB expression by thyrocytes: indication of the antigen-processing and possible presenting capability of thyroid cells. Clin Exp Immunol 116 (1999) 62-69
35. Bottazzo G.F., Pujol-Borrell R., Hanafusa T., and Feldmann M. Role of aberrant HLA-DR expression and antigen presentation in induction of endocrine autoimmunity. Lancet 2 (1983) 1115-1119
36. Bottazzo G.F., Dean B.M., McNally J.M., MacKay E.H., Swift P.G., and Gamble D.R. In situ characterization of autoimmune phenomena and expression of HLA molecules in the pancreas in diabetic insulitis. N Engl J Med 313 (1985) 353-360
37. Burmester G.R., Jahn B., Rohwer P., Zacher J., Winchester R.J., and Kalden J.R. Differential expression of Ia antigens by rheumatoid synovial lining cells. J Clin Invest 80 (1987) 595-604
38. Bottazzo G.F., Londei M., Bosi E., Mirakian R., Belfiore A., De Berardinis P.G., et al. Inappropriate HLA class II expression on epithelial cells: new insight in the pathogenesis of distinctive autoimmunity. Ann Ital Med Int 1 Suppl 1 (1986) 20-23
39. Chao M.J., Barnardo M.C., Lui G.Z., Lincoln M.R., Ramagopalan S.V., Herrera B.M., et al. Transmission of class I/II multi-locus MHC haplotypes and multiple sclerosis susceptibility: accounting for linkage disequilibrium. Hum Mol Genet 16 (2007) 1951-1958
40. Alba A., Puertas M.C., Carrillo J., Planas R., Ampudia R., Pastor X., et al. IFN beta accelerates autoimmune type 1 diabetes in nonobese diabetic mice and breaks the tolerance to beta cells in nondiabetes-prone mice. J Immunol 173 (2004) 6667-6675
41. Rosloniec E.F., Latham K., and Guedez Y.B. Paradoxical roles of IFN-gamma in models of Th1-mediated autoimmunity. Arthritis Res 4 (2002) 333-336
42. Pavlovic D., van de Winkel M., van der Auwera B., Chen M.C., Schuit F., Bouwens L., et al. Effect of interferon-gamma and glucose on major histocompatibility complex class I and class II expression by pancreatic beta- and non-beta-cells. J Clin Endocrinol Metab 82 (1997) 2329-2336
43. Montani V., Shong M., Taniguchi S.I., Suzuki K., Giuliani C., Napolitano G., et al. Regulation of major histocompatibility class II gene expression in FRTL-5 thyrocytes: opposite effects of interferon and methimazole. Endocrinology 139 (1998) 290-302
44. Harris P.E., Malanga D., Liu Z., Hardy M.A., Souza F., Del Pozzo G., et al. Effect of interferon alpha on MHC class II gene expression in ex vivo human islet tissue. Biochim Biophys Acta 1762 (2006) 627-635
45. Beutler B., Jiang Z., Georgel P., Crozat K., Croker B., Rutschmann S., et al. Genetic analysis of host resistance: Toll-like receptor signaling and immunity at large. Annu Rev Immunol 24 (2006) 353-389
46. Dunne A., and O'Neill L.A. The interleukin-1 receptor/Toll-like receptor superfamily: signal transduction during inflammation and host defense. Sci STKE 2003 (2003) re3
47. Steinman R.M. Some interfaces of dendritic cell biology. Apmis 111 (2003) 675-697
48. Banchereau J., Pascual V., and Palucka A.K. Autoimmunity through cytokine-induced dendritic cell activation. Immunity 20 (2004) 539-550
49. Duncan M.R., and Berman B. Persistence of a reduced-collagen-producing phenotype in cultured scleroderma fibroblasts after short-term exposure to interferons. J Clin Invest 79 (1987) 1318-1324
50. Granstein R.D., Flotte T.J., and Amento E.P. Interferons and collagen production. J Invest Dermatol 95 (1990) 75S-80S
51. Black C.M., Silman A.J., Herrick A.I., Denton C.P., Wilson H., Newman J., et al. Interferon-alpha does not improve outcome at one year in patients with diffuse cutaneous scleroderma: results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 42 (1999) 299-305
52. Freundlich B., Jimenez S.A., Steen V.D., Medsger Jr. T.A., Szkolnicki M., and Jaffe H.S. Treatment of systemic sclerosis with recombinant interferon-gamma. A phase I/II clinical trial. Arthritis Rheum 35 (1992) 1134-1142
53. Hunzelmann N., Anders S., Fierlbeck G., Hein R., Herrmann K., Albrecht M., et al. Systemic scleroderma. Multicenter trial of 1 year of treatment with recombinant interferon gamma. Arch Dermatol 133 (1997) 609-613
54. Varga J. Recombinant cytokine treatment for scleroderma. Can the antifibrotic potential of interferon-gamma be realized clinically?. Arch Dermatol 133 (1997) 637-642
55. Arnaudova P., Rashkov R., and Tsanev R. Application of interferon-gamma containing gel for local treatment of skin ulcers in autoimmune vasculitides and skin changes in progressive systemic sclerosis. J Rheumatol 20 (1993) 1445-1446
56. Kahan A., Amor B., Menkes C.J., and Strauch G. Recombinant interferon-gamma in the treatment of systemic sclerosis. Am J Med 87 (1989) 273-277
57. Hein R., Behr J., Hundgen M., Hunzelmann N., Meurer M., Braun-Falco O., et al. Treatment of systemic sclerosis with gamma-interferon. Br J Dermatol 126 (1992) 496-501
58. Polisson R.P., Gilkeson G.S., Pyun E.H., Pisetsky D.S., Smith E.A., and Simon L.S. A multicenter trial of recombinant human interferon gamma in patients with systemic sclerosis: effects on cutaneous fibrosis and interleukin 2 receptor levels. J Rheumatol 23 (1996) 654-658
59. UK Systemic Sclerosis Study Group, Stevens W., Vancheeswaran R., and Black C.M. Alpha interferon-2a (Roferon-A) in the treatment of diffuse cutaneous systemic sclerosis: a pilot study. Br J Rheumatol 31 (1992) 683-689
60. Solans R., Bosch J.A., Esteban I., and Vilardell M. Systemic sclerosis developing in association with the use of interferon alpha therapy for chronic viral hepatitis. Clin Exp Rheumatol 22 (2004) 625-628
61. Abu-Shakra M., Sukenik S., and Buskila D. Systemic sclerosis: another rheumatic disease associated with hepatitis C virus infection. Clin Rheumatol 19 (2000) 378-380
62. Beretta L., Caronni M., Vanoli M., and Scorza R. Systemic sclerosis after interferon-alfa therapy for myeloproliferative disorders. Br J Dermatol 147 (2002) 385-386
63. Tahara H., Kojima A., Hirokawa T., Oyama T., Naganuma A., Maruta S., et al. Systemic sclerosis after interferon alphacon-1 therapy for hepatitis C. Intern Med 46 (2007) 473-476
64. Airo P., Scarsi M., Rossi M., and Mondini M. Onset and enhancement of systemic sclerosis after treatments for multiple sclerosis. Rheumatol Int (2007)
65. Hugle T., Gratzl S., Daikeler T., Frey D., Tyndall A., and Walker U.A. Sclerosing skin disorders in association with multiple sclerosis. Coincidence, underlying autoimmune pathology, or interferon induced?. Ann Rheum Dis (2008)
66. Giacomelli R., Cipriani P., Fulminis A., Barattelli G., Matucci-Cerinic M., D'Alo S., et al. Circulating gamma/delta T lymphocytes from systemic sclerosis (SSc) patients display a T helper (Th) 1 polarization. Clin Exp Immunol 125 (2001) 310-315
67. Horikawa M., Hasegawa M., Komura K., Hayakawa I., Yanaba K., Matsushita T., et al. Abnormal natural killer cell function in systemic sclerosis: altered cytokine production and defective killing activity. J Invest Dermatol 125 (2005) 731-737
68. York M.R., Nagai T., Mangini A.J., Lemaire R., van Seventer J.M., and Lafyatis R. A macrophage marker, Siglec-1, is increased on circulating monocytes in patients with systemic sclerosis and induced by type I interferons and toll-like receptor agonists. Arthritis Rheum 56 (2007) 1010-1020
69. Tan F.K., Zhou X., Mayes M.D., Gourh P., Guo X., Marcum C., et al. Signatures of differentially regulated interferon gene expression and vasculotrophism in the peripheral blood cells of systemic sclerosis patients. Rheumatology (Oxford) 45 (2006) 694-702
70. Fujii H., Hasegawa M., Takehara K., Mukaida N., and Sato S. Abnormal expression of intracellular cytokines and chemokine receptors in peripheral blood T lymphocytes from patients with systemic sclerosis. Clin Exp Immunol 130 (2002) 548-556
71. Valentini G., Baroni A., Esposito K., Naclerio C., Buommino E., Farzati A., et al. Peripheral blood T lymphocytes from systemic sclerosis patients show both Th1 and Th2 activation. J Clin Immunol 21 (2001) 210-217
72. Molteni M., Della Bella S., Mascagni B., Bazzi S., Zulian C., Compasso S., et al. Increased interferon-gamma (IFN-gamma) levels produced in vitro by alloactivated T lymphocytes in systemic sclerosis and Raynaud's phenomenon. Clin Exp Immunol 116 (1999) 164-168
73. Coelho L.F., de Oliveira J.G., de Oliveira D.B., Guedes A.C., Lanna C.C., Prados R.Z., et al. Increased expression of 2′5′oligoadenylate synthetase and double-stranded RNA dependent protein kinase messenger RNAs on affected skin of systemic sclerosis patients. Arch Dermatol Res 299 (2007) 259-262
74. Mondini M., Vidali M., De Andrea M., Azzimonti B., Airo P., D'Ambrosio R., et al. A novel autoantigen to differentiate limited cutaneous systemic sclerosis from diffuse cutaneous systemic sclerosis: the interferon-inducible gene IFI16. Arthritis Rheum 54 (2006) 3939-3944
75. Fleming J.N., Nash R.A., McLeod D.O., Fiorentino D.F., Shulman H.M., Connolly M.K., et al. Capillary regeneration in scleroderma: stem cell therapy reverses phenotype?. PLoS ONE 3 (2008) e1452
76. Magro C.M., Crowson A.N., and Ferri C. Cytomegalovirus-associated cutaneous vasculopathy and scleroderma sans inclusion body change. Hum Pathol 38 (2007) 42-49
77. Magro C.M., Wusirika R., Frambach G.E., Nuovo G.J., Ferri C., and Ross Jr. P. Autoimmune-like pulmonary disease in association with parvovirus B19: a clinical, morphologic, and molecular study of 12 cases. Appl Immunohistochem Mol Morphol 14 (2006) 208-216
78. Pirila L., Soderstrom K.O., Hietarinta M., Jalava J., Kyto V., and Toivanen A. Fatal myocardial necrosis caused by Staphylococcus lugdunensis and cytomegalovirus in a patient with scleroderma. J Clin Microbiol 44 (2006) 2295-2297
79. Ferri C., Azzi A., and Magro C.M. Parvovirus B19 and systemic sclerosis. Br J Dermatol 152 (2005) 819-820
80. Oiso N., Fukai K., Hosomi N., and Ishii M. Guttate morphoea in human T-cell lymphoma/lymphotrophic virus type-1 (HTLV-1) infection. Clin Exp Dermatol 28 (2003) 380-382
81. Ohtsuka T., and Yamazaki S. Prevalence of human cytomegalovirus DNA in scleroderma skin tissue. Int J Dermatol 45 (2006) 86-87
82. Filali S.M., Faik A., Allali F., Jahid A., Chihab W., El Hassani S., et al. Histoplasma capsulatum tenosynovitis in a patient with rheumatoid arthritis-scleroderma overlap syndrome. Joint Bone Spine 73 (2006) 479-481
83. Salpietro D.C., Merlino M.V., Bruglia S., Guarneri F., and Vaccaro M. Linear scleroderma 'en coup de sabre' associated with facial atrophy in a patient seropositive for Borrelia burgdorferi: a true case of molecular mimicry?. Pediatr Allergy Immunol 15 (2004) 570-572
84. Danese S., Zoli A., Cremonini F., and Gasbarrini A. High prevalence of Helicobacter pylori type I virulent strains in patients with systemic sclerosis. J Rheumatol 27 (2000) 1568-1569
85. Sidky Y.A., and Borden E.C. Inhibition of angiogenesis by interferons: effects on tumor- and lymphocyte-induced vascular responses. Cancer Res 47 (1987) 5155-5161
86. Indraccolo S., Pfeffer U., Minuzzo S., Esposito G., Roni V., Mandruzzato S., et al. Identification of genes selectively regulated by IFNs in endothelial cells. J Immunol 178 (2007) 1122-1135
87. Battle T.E., Lynch R.A., and Frank D.A. Signal transducer and activator of transcription 1 activation in endothelial cells is a negative regulator of angiogenesis. Cancer Res 66 (2006) 3649-3657
88. Denny M.F., Thacker S., Mehta H., Somers E.C., Dodick T., Barrat F.J., et al. Interferon-alpha promotes abnormal vasculogenesis in lupus: a potential pathway for premature atherosclerosis. Blood 110 (2007) 2907-2915
89. Lee P.Y., Li Y., Richards H.B., Chan F.S., Zhuang H., Narain S., et al. Type I interferon as a novel risk factor for endothelial progenitor cell depletion and endothelial dysfunction in systemic lupus erythematosus. Arthritis Rheum 56 (2007) 3759-3769
90. Rajagopalan S., Somers E.C., Brook R.D., Kehrer C., Pfenninger D., Lewis E., et al. Endothelial cell apoptosis in systemic lupus erythematosus: a common pathway for abnormal vascular function and thrombosis propensity. Blood 103 (2004) 3677-3683
91. Caposio P., Gugliesi F., Zannetti C., Sponza S., Mondini M., Medico E., et al. A novel role of the interferon-inducible protein IFI16 as inducer of proinflammatory molecules in endothelial cells. J Biol Chem 282 (2007) 33515-33529
92. Fairbrother W.J., Gordon N.C., Humke E.W., O'Rourke K.M., Starovasnik M.A., Yin J.P., et al. The PYRIN domain: a member of the death domain-fold superfamily. Protein Sci 10 (2001) 1911-1918
93. Staub E., Dahl E., and Rosenthal A. The DAPIN family: a novel domain links apoptotic and interferon response proteins. Trends Biochem Sci 26 (2001) 83-85
94. Seelig H.P., Ehrfeld H., and Renz M. Interferon-gamma-inducible protein p16. A new target of antinuclear antibodies in patients with systemic lupus erythematosus. Arthritis Rheum 37 (1994) 1672-1683
95. Uchida K., Akita Y., Matsuo K., Fujiwara S., Nakagawa A., Kazaoka Y., et al. Identification of specific autoantigens in Sjogren's syndrome by SEREX. Immunology 116 (2005) 53-63